A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

December 11, 2024

Study Completion Date

December 11, 2024

Conditions
Liver Cirrhosis
Interventions
DRUG

Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)

"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"

DRUG

Zibotentan + placebo (placebo matching dapagliflozin tablet)

"zibotentan capsule~placebo tablet (matching dapagliflozin tablet)"

DRUG

Zibotentan + dapagliflozin

"zibotentan capsule~dapagliflozin 10 mg tablet"

Trial Locations (34)

2217

Research Site, Kogarah

2800

Research Site, Mechelen

3132

Research Site, Mitcham

5000

Research Site, Adelaide

20122

Research Site, Milan

29425

Research Site, Charleston

35128

Research Site, Padua

72076

Research Site, Tübingen

78215

Research Site, San Antonio

80113

Research Site, Englewood

83104

Research Site, Bratislava

91702

Research Site, Trnava

460 63

Research Site, Liberec

293 01

Research Site, Mladá Boleslav

140 21

Research Site, Prague

04103

Research Site, Leipzig

00168

Research Site, Roma

500-8513

Research Site, Gifu

215-0026

Research Site, Kawasaki-shi

806-8501

Research Site, Kitakyusyu-shi

940-2085

Research Site, Nagaoka-shi

951-8520

Research Site, Niigata

006-8555

Research Site, Sapporo

236-0004

Research Site, Yokohama

85-794

Research Site, Bydgoszcz

40-081

Research Site, Katowice

41-400

Research Site, Mysłowice

61-848

Research Site, Poznan

950 01

Research Site, Nitra

AB25 2ZN

Research Site, Aberdeen

HU3 2KZ

Research Site, Hull

IP4 5PD

Research Site, Ipswich

SE5 9RS

Research Site, London

NG7 2UH

Research Site, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY